Last reviewed · How we verify

NCT05626088

A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

Active, enrolled Last updated 25 February 2026
What this trial tests

trial testing No Intervention in Ulcerative Colitis in 1,006 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
10 April 2023
Primary endpoint
27 December 2024
29 May 2026

Quick facts

Lead sponsorTakeda
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment1,006
Start date10 April 2023
Primary completion27 December 2024
Estimated completion29 May 2026
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Ulcerative Colitis or Crohn's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary reason of this study is to observe current and past treatment in adult participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Brazil. There is no treatment involved in this study, this is only an observational review of past and ongoing treatment data relating to Vedolizumab treatment for IBD (including Ulcerative Colitis \[UC\] and Crohn's Disease \[CD\]).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

Other Takeda trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05626088.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing